Original document(23 pages)  中文版
    A quality control method for the Chinese medicine used to treat depression includes such steps as checking its characteristics, discrimination to cablin potchouli herb, atractylodes rhizome, katsumadai seed and tangerine peel, and measuring the content of hesperidin.
Application Number
申请号		 200510200866 Application Date
申请日		 2005.12.27
Title 名称 Quality control method of medicinal preparation for treating lypemania
Publication Number
公开号		 1824238 Publication Date
公开日		 2006.08.30
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K36/9064,A61K9/16,A61K9/20,A61K9/48,A61P25/24,G01N30/90,G01N33/15
Applicant(s) Name
申请人		 Guizhou Tongjitang Pharmaceutical Co., Ltd.
Address 地址 550001
Inventor(s) Name 发明人 Huang Lugi, Fu Meihong, Yang Hua, Nie Shuqin
Attorney & Agent 代理人 guo fang

  
Process for identifing real and flase of chinese herbal medicine black-striped snake by high specificity polyase chain type reaction technology
Depression treating medicinal formulation and its preparation process
Quality control method of kidney beneficial bone fortifying capsule
Shenshu Jianpi medicinal preparation for invigorating spleen and its new preparation method
Medicinal preparation and its new preparation method
Sancaifengsui medicinal preparation and its new preparation method
Menstruation regulating blood nourishing medicinal preparation and its new preparation method
Quelity control method of Chinese medicinal preparation for hepatatitis toxin resolving
Quality control method of bone sinew medicinal pill preparation
Medicinal film vest medicinal film plaster for treating coronary heart disease stenocardia and preventing myocardial infaction and its preparation method
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.